Press Release on financial results for Q4FY26 and Year ended March 31, 2026
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies reported strong FY26 results with revenue up 17.3% to ₹1,403.2 Cr and PAT up 33.4% to ₹199.4 Cr (including one-time statutory impact of ₹14.3 Cr post-tax from New Labor Code). Q4FY26 revenue grew 20.2% YoY to ₹353.1 Cr. PAT margins expanded significantly to 14.2% in FY26 vs 12.5% in FY25 (+172 bps), while EBITDA margins improved to 20.9% (+85 bps). The company acquired WOKADINE to enter the ₹648 Cr Povidone Iodine market, relaunched key brands (Fosine R, Menodac, Noklot), and established a dedicated team for the infertility segment. Two brands crossed the ₹100 Cr MAT milestone. Industry ranking improved to 27th from 32nd over three years. EAEU-GMP certification enables entry into Russia and neighboring markets.
Strong margin expansion and robust PAT growth signal operational efficiency gains and brand strength. The strategic WOKADINE acquisition and multi-market expansion support long-term growth, but the one-time labor code impact means underlying PAT growth is slightly lower than headline figures.